| Dr Michael Adelard Carron, MD | |
|
5250 Auto Club Dr Ste 290a, Dearborn, MI 48126-2619 | |
| (313) 448-9220 | |
| Not Available |
| Full Name | Dr Michael Adelard Carron |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 22 Years |
| Location | 5250 Auto Club Dr Ste 290a, Dearborn, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568670156 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YS0123X | Otolaryngology - Facial Plastic Surgery | 4301080650 (Michigan) | Secondary |
| 207Y00000X | Otolaryngology | 4301080650 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital - Dearborn | Dearborn, MI | Hospital |
| Mclaren Macomb | Mount clemens, MI | Hospital |
| Harper University Hospital | Detroit, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mclaren Medical Group | 3971416082 | 187 |
| University Physician Group | 8628087681 | 345 |
News Archive
Recognizing faces is an important social skill, but not all of us are equally good at it. Some people are unable to recognize even their closest friends (a condition called prosopagnosia), while others have a near-photographic memory for large numbers of faces.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Today's headlines include reports about the White House's strategy for building support for the health law.
Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
› Verified 3 days ago
| Entity Name | Mclaren Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346396066 PECOS PAC ID: 3971416082 Enrollment ID: O20031106000025 |
News Archive
Recognizing faces is an important social skill, but not all of us are equally good at it. Some people are unable to recognize even their closest friends (a condition called prosopagnosia), while others have a near-photographic memory for large numbers of faces.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Today's headlines include reports about the White House's strategy for building support for the health law.
Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
› Verified 3 days ago
| Entity Name | University Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447299797 PECOS PAC ID: 8628087681 Enrollment ID: O20060419000518 |
News Archive
Recognizing faces is an important social skill, but not all of us are equally good at it. Some people are unable to recognize even their closest friends (a condition called prosopagnosia), while others have a near-photographic memory for large numbers of faces.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Today's headlines include reports about the White House's strategy for building support for the health law.
Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Adelard Carron, MD 400 Mack Ave., Credentialing Dept., Detroit, MI 48201-2136 Ph: (313) 448-9006 | Dr Michael Adelard Carron, MD 5250 Auto Club Dr Ste 290a, Dearborn, MI 48126-2619 Ph: (313) 448-9220 |
News Archive
Recognizing faces is an important social skill, but not all of us are equally good at it. Some people are unable to recognize even their closest friends (a condition called prosopagnosia), while others have a near-photographic memory for large numbers of faces.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Today's headlines include reports about the White House's strategy for building support for the health law.
Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.
› Verified 3 days ago
Dr. Roger Sabah Toma, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2421 Monroe St, Suite 201, Dearborn, MI 48124 Phone: 313-562-4100 | |
Nouha Alammar, D.O Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 24530 Michigan Ave, Dearborn, MI 48124 Phone: 313-681-5300 Fax: 313-749-7882 | |
Mr. Mark Sabah Toma, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2421 Monroe St, Suite 201, Dearborn, MI 48124 Phone: 313-562-4100 Fax: 313-562-4590 | |
Dr. Ariel Andre Waitzman, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 22731 Newman Street, Ste 120, Dearborn, MI 48124 Phone: 313-582-8853 Fax: 313-582-6417 | |
Werner C. Roennecke, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: Henry Ford Health System, 19401 Hubbard Drive, Dearborn, MI 48126 Phone: 313-982-8330 Fax: 313-982-8294 |